Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

514
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
514

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

<i>Azospirillum caeni</i> sp. nov., a mesotrione-resistant and nitrogen-fixing bacterium isolated from an activated sludge.

International journal of systematic and evolutionary microbiology·2026
Same author

Tafenoquine: A Breakthrough Option for Babesiosis Treatment.

Tropical medicine and infectious disease·2026
Same author

Topography-dependent Prognostic Value of CDK5 in Cetuximab-Treated, RAS/BRAF-wild-type Metastatic Colorectal Cancer: A Retrospective Tissue-Microarray Analysis.

Cancer control : journal of the Moffitt Cancer Center·2026
Same author

Novel Catabolic Pathway of Mesotrione and Its Metabolite AMBA by a Newly Mesotrione-Degrading Strain <i>Staphylococcus saprophyticus</i> B05.

Journal of agricultural and food chemistry·2026
Same author

First Isolation of Bovine Coronavirus From Yanbian, China, and Analytical Validation of a SYBR Green I RT-qPCR Panel for Calf Diarrhea Viruses.

Transboundary and emerging diseases·2026
Same author

Astragaloside IV delays vascular aging by enhancing mitochondrial fatty acid β-oxidation via the MLXIPL-PPARα/PGC-1α axis.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026

相关实验视频

Updated: Jun 25, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K

用免疫检查点抑制剂治疗的固体瘤中的预后因素NRS2002得分:现实世界的证据分析.

Wanfen Tang1, Chenghui Li1, Dong Huang2

  • 1Department of Medical Oncology, Jinhua Municipal Central Hospital, Hangzhou, China.

Cancer biology & therapy
|May 30, 2024
PubMed
概括

根据NRS2002评分评估的营养风险,显著影响了癌症免疫治疗的结果. 没有营养风险的患者表现出更好的无进展生存率和免疫检查点抑制剂治疗的整体生存率.

关键词:
营养风险查 (NRS) 2002 年瘤免疫检查点抑制剂疗法癌症营养 癌症营养现实世界的研究研究.

更多相关视频

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment &#8212; Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.3K

相关实验视频

Last Updated: Jun 25, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment &#8212; Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.3K

科学领域:

  • 在瘤学瘤学.
  • 免疫治疗是一种免疫疗法.
  • 营养科学 营养科学

背景情况:

  • 免疫检查点抑制剂 (ICI) 代表了癌症治疗的重大进展.
  • 现实世界的数据对于了解临床试验之外的ICI疗效至关重要.
  • 营养状况越来越被认为是影响癌症患者结果的因素.

研究的目的:

  • 为了评估编程死亡1 (PD-1) 抑制剂的真实世界抗瘤疗效.
  • 探索NRS2002得分和其他临床因素与ICI治疗疗效之间的关联.
  • 在接受免疫治疗的患者中确定NRS2002得分的预后值.

主要方法:

  • 在2018年6月至2021年12月期间,对341名实体瘤患者进行了ICI治疗的回顾性分析.
  • 患者特征,ICI反应和生存状况的记录.
  • 统计分析包括单变量分析和考克斯回归来确定预后因素.

主要成果:

  • 无进展生存时间 (PFS) 中位数为5.8个月,总生存时间 (OS) 中位数为12.5个月.
  • NRS2002得分,绩效状态 (PS),那不勒斯预后得分 (NPS),LCR,治疗线和营养支持与PFS或OS有关.
  • 没有营养风险的患者 (NRS2002 0-2) 与营养风险 (NRS2002 ≥3) 患者相比,显著改善了PFS和OS.
  • NRS2002得分是PFS和OS的独立预后因素.
  • 有营养风险的患者 (8.33%) 与没有营养风险的患者 (19.71%) 的客观反应率 (ORR) 较低.

结论:

  • 根据NRS2002得分,具有营养风险的患者在ICI治疗期间的预后较差.
  • NRS2002得分可以作为预测免疫检查点抑制剂疗法的疗效的初步指数.
  • 解决营养状况对于优化免疫治疗患者的治疗结果可能很重要.